Investor Presentation First Nine Months of 2022
9
Investor presentation First nine months of 2022
Novo NordiskⓇ
Obesity care sales grew by 75% in the first nine months of 2022
driven by both the US and IO
NN sales and value market share
DKK billion
3%1
5
4
3
2
1
within Obesity care
Global Branded AOM TRX
TRX count ('000s)
55%1
75%1
100%
500
86%
400
300
50%
200
0
0%
2020
2021
2022
IO
NAO
-Market share (RHS)
100
+63%
2020
2021
2022
Novo Nordisk
Others
ONCE-WEEKLY
wegovy
semaglutide injection 2.4 mg
The US
.
·
•
Broad commercial formulary access
of more than 80%
The 1.7 mg and 2.4 mg doses are
currently available in the US
Expectation to make all WegovyⓇ
doses available towards the end of
2022
International Operations
•
WegovyⓇ available in France with first
ex-US commercial launches expected
towards the end of 2022
Growth at CER
1 Annual growth at CER. Each TRx data points represents one week of data
NAO: North America operations; IO: International operations; RHS: Right-hand side axis; Rx: Prescriptions; AOM: Anti-Obesity Medications (includes Wegovy®, SaxendaⓇ, Qsymia, Belviq and Contrave); Mg: milligram; CMO: Contract manufacturing organisation
Note: Sales growth at constant exchange rates. 63% volume growth for Global branded AOM market refers to MAT.
Source: IQVIA MAT, Aug 2022 (Spot rate)View entire presentation